AMRI to be Acquired by The Carlyle Group
The company will be acquired for $21.75 per share in cash.
On June 6, 2017, AMRI announced that it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group for $21.75 per share in cash. The agreement was unanimously approved by AMRI's Board of Directors, which has recommended that the shareholders vote in favor of the transaction.
Closing of the transaction is subject to customary closing conditions. It is anticipated that the special meeting of AMRI's stockholders to vote on the transaction will be held in the third quarter of 2017, and if the transaction is approved, the merger would be expected to close shortly thereafter.
Source: AMRI
EXO Biologics and ExoXpert Reach Two Critical Milestones that Advance Exosomes
December 3rd 2024EXO Biologics and its subsidiary, ExoXpert, have received GMP certification of a European exosomes manufacturing facility and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
